Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


27. March 2020 | 14:20 CET

Drägerwerk or Micro-X - how do investors benefit from the Corona Pandemic?

  • Healthcare

The current Corona Pandemic is challenging people around the globe. Doctors and medical staff are under particular strain. For some time now, it has become clear that there is a lack of material and equipment to withstand a large onslaught of infected Covid-19 patients. In order to slow down the spread of the virus, the population is urged to avoid social contacts. Manufacturers of equipment and materials for the medical sector are now being flooded with orders to compensate for the shortage, and investors have the opportunity to make a financial investment.

time to read: 1 minutes by Mario Hose


 

Federal government fills supply gap

The ventilators and medical protective equipment of Drägerwerk AG & Co. KGaA are in great demand. Two weeks ago, the company received a major order from the German government. According to the announcement, the delivery of 10,000 ventilators and protective equipment for medical personnel was agreed. The delivery will cover the next 12 months. This order is directly related to the spread of the corona virus and will be used to supply the healthcare system.

Product to combat shortages

In addition to ventilators, X-ray equipment is also needed to monitor the course of the disease in the patient's lungs. In recent years, the Australian company Micro-X Limited has developed a mobile X-ray unit that is now going into series production. The device is called the Carestream DRX Revolution Nano. The advantage is that the device can be moved, which increases the treatment comfort of the patients.

Based on the demand for the devices, the company will adapt its growth strategy and immediately initiate operational measures originally planned for a later date, Micro-X recently announced. As hospitals are now the focus of events and gaps in medical care are becoming apparent, more money is expected to flow into healthcare now and in the future.

Sales increase significantly

While Drägerwerk is a traditional billion-dollar company, at Micro-X investors can enter a growth story that is now experiencing high demand. In the past fiscal year, the company generated sales of AUD 1.9 million and was already able to announce incoming orders of AUD 2.4 million in the first quarter of 2020.

Micro-X's market capitalisation is currently AUD 31.25 million at the closing price of AUD 0.125 on the home exchange ASX. The shares of the company are not (yet) listed in Germany but information on the security is available and trading on the ASX is possible via the following details: ISIN: AU0000MX15, WKN: A2ACCY, ASX: MX1 or via the website: micro-x.com.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

18. June 2020 | 08:40 CET

BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?

  • Healthcare

Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.

Read

16. June 2020 | 06:30 CET

Gilead, Teva, XPhyto - Global marketing potential

  • Healthcare

The best business models solve problems and are scalable. In this context, the healthcare sector is particularly interesting. The world's population has recently reached 7.8 billion people and for this reason solutions can meet a large potential market with users. Cross-border solutions are needed not only for pandemics, but also for diseases that are not mentioned in the mass media but are nevertheless of great importance. A successful market launch is of equal interest to those affected and investors.

Read

02. June 2020 | 05:58 CET

Memphasys, Moderna, Paion - Investments in solutions with potential

  • Healthcare

Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive this process is, the more capital these companies require from investors. In the race to bring to market preparations or products that improve people's well-being or fulfill desires, the providers of solutions usually have great sales potential and investors may be bought out through a takeover.

Read